Slide 1

415 / 1631

–100
–50
0
50
100
Ansell et al; ASH 2015
Percent Change From Baselinein Target Lesions/Tumor Burden
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114
On treatment, ongoing response
Off treatment without progression
Progressive disease, following response
or stable disease
▪ First occurrence of new lesion
Nivolumab in r&r HL
Durability of response